Abstracts

Extended Nirmatrelvir/Ritonavir Treatment Durations for Immunocompromised Patients With COVID-19

Background: Nirmatrelvir/ritonavir (NMV/r) is an FDA-approved treatment for adults with mild to moderate COVID-19 who are at high risk for progression to severe disease. Limited data support dosing recommendations in immunocompromised (IC) patients. This study compared the approved 5-day regimen with 10- and 15-day regimens in IC patients. Methods: This multinational, randomized, double-blind, phase 2…

Pharmaco-Virological Outcome and Resistance Profiles Among Togolese Adolescents Transitioning to DTG

Background: Very few data are available regarding efficacy of the transition to tenofovir-lamivudine-dolutegravir (TLD) among adolescents living with HIV (ALHIV) in West Africa. Here, we assessed pharmaco-virological outcome and resistance profiles among ARV-treated Togolese ALHIV. Methods: A cross-sectional study was conducted among 3 clinical centers in Lomé, capital of Togo, following ALHIV. Plasma HIV viral…

LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL

Background: Pre-exposure prophylaxis (PrEP) is an important strategy for HIV prevention among people at risk. Long-acting antiretroviral agents circumvent the requirement for daily dosing to achieve maximal protection and represent an alternative to daily oral regimens. Lenacapavir (LEN) is a long-acting HIV capsid inhibitor recently approved in the European Union for the treatment of multi-drug-resistant…

EFFECTS OF 6-MONTH PREP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA

Background: Six-month PrEP dispensing supported with interim HIV self-testing (HIVST) was shown to be non-inferior compared to 3-month PrEP dispensing with clinic-based HIV testing, the standard of care (SOC), for PrEP continuation outcomes in Kenya. We assessed the effects of this differentiated service delivery (DSD) model for PrEP on sexual behaviors. Methods: The JiPime-JiPrEP trial…

EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS

Background: On-demand HIV prevention modalities used before or after vaginal sex may be a desirable alternative to daily oral pre-exposure prophylaxis (PrEP) for women with infrequent or clustered sexual activity. CONRAD has developed inserts containing tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG) that were safe, well accepted, and showed good pharmacokinetics and pharmacodynamics in a…

PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT

Background: Long-acting injectables (LAIs) for HIV PrEP can increase adherence and reduce stigma. Current LAIs are not removable and present a pharmacokinetic (PK) tail. To overcome these limitations, we developed an ultra-long-acting (ULA) biodegradable and removable in situ forming implant (ISFI) with cabotegravir (CAB). Here, we performed a PK study evaluating injection volume (IVOL), drug…

VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES

Background: Islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, is in development for long-acting pre-exposure prophylaxis (LA PrEP) as a monthly pill and subdermal implant. ISL is on clinical hold after lymphopenia was observed in clinical trials. Here we investigated in macaques ISL implants with varied release rates and assessed safety, pharmacokinetics, and vaginal efficacy…